Dhawaan, daraasaddii Antengene ee Marxaladda I/II CLINCH ee ATG-022 (CLDN18.2 antibody-drug conjugate), oo ah bukaan da' ah oo qaba kansarka caloosha oo horumarsan kaasoo ku horumaray dhowr nooc oo kiimoterabi ah, daaweynta difaaca jirka iyo daaweynta bartilmaameedsan inkastoo metastases ballaaran ay gaareen jawaab dhammaystiran (CR) ka dib daaweynta ATG-022 ee monotherapy. Xaaladda bukaanka ee aan lahayn burooyinka waxaa xaqiijiyay PET/CT bishii Maajo 2025.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
ATG-022 waa CLDN18.2 ADC oo ay Antengene ogaatay oo ay ku samaysay gudaha. Shirkii ASCO GI 2025 horraantii sannadkan, Antengene waxay soo bandhigtay xog caafimaad oo la cusbooneysiiyay oo ku saabsan ATG-022. Bukaannada qaba muujinta CLDN18.2 ee dhexdhexaadka ah ilaa sare (IHC 2+ ≥ 20%), heerka jawaab celinta ujeeddada (ORR) wuxuu ahaa 42.9%, heerka xakamaynta cudurka (DCR) wuxuu ahaa 95.2%. Bukaannada qaba muujinta CLDN18.2 ee hooseeya (IHC 2+ < 20%), ORR wuxuu ahaa 30.0%, DCR-na wuxuu ahaa 50.0%. Xogtani waxay muujinaysaa in ATG-022 ay bixiso waxtar kiliinikada ah oo macno leh iyo astaan badbaado oo wanaagsan oo ku baahsan heerarka muujinta CLDN18.2, oo ay ku jiraan muujinta sare, hoose, iyo xitaa aadka u hooseysa. Hawlgalkeeda ka hortagga burooyinka ee ballaaran ayaa soo jeedinaya in ATG-022 ay faa'iidooyin daaweyn ah u yeelan karto dad badan oo bukaan ah marka loo eego daawaynta kale ee bartilmaameedsan ee CLDN18.2. Waqtigan xaadirka ah, daraasadda ballaarinta qiyaasta wejiga labaad ee ATG-022 ayaa ka socota dhul-weynaha Shiinaha iyo Australia.
Guushan CR ee bukaankan da'da ah ee kansarka caloosha ku dhaca waa mid aad u dhiirigelin leh, taasoo muujinaysa awoodda daaweynta ee ATG-022 oo ah daaweyn cusub oo ADC ah. Muhiimad ahaan, kani maaha CR-ga kaliya ee lagu arkay daraasadda socota. Ilaa hadda, saddex kiis oo CR ah ayaa la arkay, oo ay ku jiraan bukaanada ka yimid dhul-weynaha Shiinaha iyo Australia. Antengene waxay rajeyneysaa inay soo bandhigto xog cusub oo ka timid daraasadda ATG-022 ee Shirweynaha ESMO ee soo socda Oktoobar 2025.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Waqtiga boostada: Agoosto-21-2025